Quality of life issues in non-small cell lung cancer

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 4, Issue 2, 2004, Pages 215-226

  Stephens, Richard ^a  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

Chemotherapy; Compliance; Non small cell lung cancer; Quality of life; Radiotherapy; Sample size

Indexed keywords

ADENOSINE TRIPHOSPHATE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; HYDROXYZINE; IFOSFAMIDE; LOMUSTINE; MELATONIN; METHOTREXATE; MITOMYCIN; NAVELBINE; PACLITAXEL; TENIPOSIDE; VINBLASTINE; VINDESINE;

ALOPECIA; ANALYTIC METHOD; BRACHYTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER PALLIATIVE THERAPY; CANCER SCREENING; CANCER SURVIVAL; CLINICAL TRIAL; CROSS REACTION; DRUG ERUPTION; DYSPHAGIA; ESOPHAGITIS; FATIGUE; HAIR LOSS; HEMOPTYSIS; HUMAN; LUNG NON SMALL CELL CANCER; MEDICAL DECISION MAKING; NAUSEA; PATIENT COMPLIANCE; QUALITY OF LIFE; REVIEW; SAMPLE SIZE; SKIN MANIFESTATION; STOMATITIS; VOMITING;

EID: 1842607363     PISSN: 14737167     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737167.4.2.215     Document Type: Review

References (89)

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2, 533-543 (2001).
2. Bottomley A, Efficace F, Thomas R, Vanvoorden V, Ahmedzai SH. Health-related quality of life in non-small cell lung cancer: methodologic issues in randomised controlled trials. J. Clin. Oncol. 21, 2982-2992 (2003).
3. Saunders M, Dische S, Barrett A, Harvey A, Gibson D, Parmar M on behalf of the CHART Steering Committee. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: A randomised multicentre trial. Lancet 350, 161-165 (1997).
4. Cullen MH, Billingham LJ, Woodruffe CM et al. Mitomycin, ifosfamide and cisplatin in unresectable non-small cell lung cancer: effects on survival and quality of life. J. Clin. Oncol. 17, 3188-3194 (1999).
5. Helsing M, Bergman B, Thaning L, Hero U. Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicentre randomised Phase III trial. Eur. J. Cancer 34, 1036-1044 (1998).
6. Thongprasert S, Sanguanmitra P, Juthapan W, Clinch J. Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: Best supportive care (BSC) versus BSC plus chemotherapy. Lung Cancer 24, 17-24 (1999).
7. Anderson H, Hopwood P, Stephens RJ et al. Gemcitabine plus best supportive care (BSC) versus BSC in inoperable non-small cell lung cancer - a randomised trial with quality of life as the primary outcome. Br. J. Cancer 83, 447-453 (2000).
8. Ranson M, Davidson N, Nicolson M et al. Randomised trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small cell lung cancer. J. Natl Cancer Inst. 92, 1074-1080 (2000).
9. Roszkowski K, Pluzanska A, Krzakowski M et al. A multicenter randomised Phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or nonresectable localized non-small cell lung cancer (NSCLC). Lung Cancer 27, 145-157 (2000).
10. Gridelli C. The ELVIS trial: A Phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer. Oncologist 6(Suppl. 1), 4-7 (2001).
11. Crawford J, O'Rourke M, Schiller JH et al. Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small cell lung cancer. J. Clin. Oncol. 14, 2774-2784 (1996).
12. Buccheri G, Ferrigno D. Efficacy of platinum-based regimens in non-small cell lung cancer: A negative report from the Cuneo Lung Cancer Study Group. Lung Cancer 18, 57-70 (1997).
13. Giaccone G, Splinter TAW, Debruyne C et al. Randomised study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small cell lung cancer. J. Clin. Oncol. 16, 2133-2141 (1998).
14. Cardenal F, Lopez-Cabrerizo MP, Anton A et al. Randomised Phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer. J. Clin. Oncol. 17, 12-18 (1999).
15. Comella P, Frasci G, Panza N et al. Cisplatin, gemcitabine and vinorelbine combination therapy in advanced non-small cell lung cancer: A Phase II randomized study of the Southern Italy Cooperative Oncology Group. J. Clin. Oncol. 17, 1526-1534 (1999).
16. Crino L, Scagliotti GV, Ricci C et al. Gemcitabine and cisplatin versus mitomycin, ifosfamide and cisplatin in advanced non-small cell lung cancer: A randomised Phase III study of the Italian Lung Cancer Project. J. Clin. Oncol. 17, 3522-3530 (1999).
17. ten Bokkel Huinink WW, Bergman B, Chemaissani A et al. Single-agent gemcitabine: An active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancer. Lung Cancer 26, 85-94 (1999).
18. Bonomi P, Kim KM, Fairclough D et al. Comparison of survival and quality of life in advanced non-small cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an Eastern Co-operative Oncology Group trial. J. Clin. Oncol. 18, 623-631 (2000).
19. Gatzemeier U, von Pawel J, Gottfried M et al. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small cell lung cancer. J. Clin. Oncol. 18, 3390-3399 (2000).
20. Sandler AB, Nemunaitis J, Denham C et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small cell lung cancer. J. Clin. Oncol. 18, 122-130 (2000).
21. Frasci G, Lorusso V, Panza N et al. Gemcitabine plus vinorelbine yields better survival outcome than vinorelbine alone in elderly patients with advanced non-small cell lung cancer. A Southern Italy Co-operative Oncology Group (SICOG) Phase III trial. Lung Cancer 34(Suppl. 4), S65-S69 (2001).
22. Kelly K, Crowley J, Bunn PA Jr et al. Randomized Phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer: A Southwest Oncology Group trial. J. Clin. Oncol. 19, 3210-3218 (2001).
23. Rosell R, Gatzemeier U, Betticher DC et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/ cisplatin in patients with advanced non-small cell lung cancer: A co-operative multinational trial. Ann. Oncol. 13, 1539-1549 (2002).
24. Souquet PJ, Tan EH, Rodrigues Pereira J et al. GLOB-1: A prospective randomised clinical Phase III trial comparing vinorelbine-cisplatin with vinorelbine-ifosfamide-cisplatin in metastatic non-small cell lung cancer patients. Ann. Oncol. 13, 1853-1861 (2002).
25. Fossella F, Pereira JR, von Pawel J et al. Randomized, multinational, Phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small cell lung cancer: The TAX 326 study group. J. Clin. Oncol. 21, 3016-3024 (2003).
26. Gridelli C, Gallo C, Shepherd FA et al. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small cell lung cancer: A Phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 21, 3025-3034 (2003).
27. Gridelli C, Perrone F, Gallo C et al. Chemotherapy for elderly patients with advanced non-small cell lung cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) Phase III randomized trial. J. Natl Cancer Inst. 95, 362-372 (2003).
28. Smit EF, van Meerbeeck JP, Lianes P et al. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small cell lung cancer: A Phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group-EORTC 08975. J. Clin. Oncol. 21, 3909-3917 (2003).
29. Vansteenkiste J, Vandebroek J, Nackaerts K et al. Influence of cisplatin-use, age, performance status and duration of chemotherapy on symptom control in advanced non-small cell lung cancer: Detailed symptom analysis of a randomised study comparing cisplatin-vindesine to gemcitabine. Lung Cancer 40, 191-199 (2003).
30. Wachters FM, Van Putten JW, Kramer H et al. First-line gemcitabine with cisplatin or epirubicin in advanced non-small cell lung cancer: A Phase III trial. Br. J. Cancer 89, 1192-1199 (2003).
31. Paccagnella A, Favaretto A, Oniga F et al. Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non-small cell lung cancer. A multicenter, randomized Phase III trial. Lung Cancer 43, 83-91 (2004).
32. Kubota K, Watanabe K, Kunitoh H et al. Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small cell lung cancer: The Japanese Taxotere Lung Cancer Study Group. J. Clin. Oncol. 22, 254-261 (2004).
33. Buccheri GF, Ferrigno D, Curcio A, Vola F, Rosso A. Continuation of chemotherapy versus supportive care alone in patients with inoperable non-small cell lung cancer and stable disease after two or three cycles of MACC. Cancer 63, 428-432 (1989).
34. Smith IE, O'Brien MER, Talbot DC et al. Duration of chemotherapy in advanced non-small cell lung cancer: A randomised trial of three versus six courses of mitomycin, vinblastine and cisplatin. J. Clin. Oncol. 19, 1336-1343 (2001).
35. Socinski MA, Schell MJ, Peterman A et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced stage IIIb/IV non-small cell lung cancer. J. Clin. Oncol. 20, 1335-1343 (2002).
36. Shepherd FA, Dancey J, Ramlau R et al. Prospective randomised trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol. 18, 2095-2103 (2000).
37. Kosty MP, Fleishman SB, Herndon JE II et al. Cisplatin, vinblastine and hydrazine sulfate in advanced, non-small cell lung cancer: A randomized placebo-controlled, double-blind Phase III study of the Cancer and Leukemia Group B. J. Clin. Oncol. 12, 1113-1120 (1994).
38. Agteresch HJ, Dagnelie PC, van der Gaast A, Stijnen T, Wilson JH. Randomized clinical trial of adenosine 5′-triphosphate in patients with advanced non-small cell lung cancer. J. Natl Cancer Inst. 92, 321-328 (2000).
39. Fukuoka M, Yano S, Giaccone G et al. Multi-institutional randomized Phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer. J. Clin. Oncol. 21, 2237-2246 (2003).
40. Lissoni P, Chilelli M, Villa S, Cerizza I, Tancini G. Five years survival in metastatic non-small cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: A randomized trial. J. Pineal Res. 35, 12-15 (2003).
41. Kaasa S, Mastekaasa A, Thorud E. Toxicity, physical function and everyday activity reported by patients with inoperable non-small cell lung cancer in a randomized trial (chemotherapy versus radiotherapy). Acta Oncol. 27, 343-349 (1988).
42. Medical Research Council Lung Cancer Working Party. Inoperable non-small cell lung cancer (NSCLC): A Medical Research Council randomised trial of palliative radiotherapy with two fractions or ten fractions. Report to the Medical Research Council by its Lung Cancer Working Party. Br. J. Cancer. 63, 265-270 (1991).
43. Medical Research Council Lung Cancer Working Party. Randomized trial of palliative two-fraction versus more intensive 13-fraction radiotherapy for patients with inoperable non-small cell lung cancer and good performance status. Medical Research Council Lung Cancer Working Party. Clin. Oncol. 8, 167-175 (1996).
44. Ball D, Smith J, Bishop J et al. A Phase III study of radiotherapy with and without continuous-infusion fluorouracil as palliation for non-small cell lung cancer. Br. J. Cancer 75, 690-697 (1997).
45. Stout R, Barber P, Burt P et al. Clinical and quality of life outcomes in the first United Kingdom randomized trial of endobronchial brachytherapy (intraluminal radiotherapy) versus external beam radiotherapy in the palliative treatment of inoperable non-small cell lung cancer. Rad. Oncol. 56, 323-327 (2000).
46. Langendijk H, de Jong J, Tjwa M et al. External irradiation versus external irradiation plus endobronchial brachytherapy in inoperable non-small cell lung cancer: A prospective randomised study. Rad Oncol 58, 257-268 (2001).
47. Falk SJ, Girling DJ, White RJ et al. Medical Research Council Lung Cancer Working Party. Immediate versus delayed palliative thoracic radiotherapy in patients with unresectable locally advanced non-small cell lung cancer and minimal thoracic symptoms: Randomised controlled trial. Br. Med. J. 325, 465-468 (2002).
48. Myrdal G, Vlatysdottir S, Lambe M, Stahle E. Quality of life following lung cancer surgery. Thorax 58, 194-197 (2003).
49. Sarna L, Padilla G, Holmes C, Tashkin D, Brecht ML, Evangelista L. Quality of life of long-term survivors of non-small cell lung cancer. J. Clin. Oncol. 20, 2920-2929 (2002).
50. Postoperative Radiotherapy Meta-analysis Trialists Group. Postoperative radiotherapy in non-small cell lung cancer: Systematic review and meta-analysis of individual patient data from nine randomised controlled trials. Lancet 352, 257-263 (1998).
51. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br. Med. J. 311, 899-909 (1995).
52. Waller D, Fairlamb DJ, Gower N et al. The Big Lung Trial (BLT): Determining the value of cisplatin-based chemotherapy for all patients with non-small cell lung cancer (NSCLC). Preliminary results in the surgical setting. Lung Cancer 41(Suppl. 2), S54, abs O-179 (2003).
53. Scagliotti GV, Fossati R, Torri V et al. Randomised study of adjuvant chemotherapy for completely resected stage I, II or IIIa non-small cell lung cancer. J. Nat. Cancer Inst. 95, 1453-1461 (2003).
54. Le Chevalier T, for the IALT investigators. Results of the randomised international adjuvant lung cancer trial (IALT): cisplatin-based chemotherapy (CT) versus no CT in 1867 patients (pts) with resected non-small cell lung cancer (NSCLC). Proceed. Am. Soc. Clin. Onc. 22, 2, abs 6 (2003).
55. Kato H, Tsuboi M, Ohta M et al. A randomised Phase III trial of adjuvant chemotherapy with UFT for completely resected pathological stage I (T1N0M0, T2N0M0) adenocarcinoma of the lung. Proceed. Am. Soc. Clin. Onc. 22, 621, abs 2498 (2003).
56. Roth JA, Atkinson EN, Fossella F et al. Long-term follow-up of patients enrolled in a randomised trial comparing perioperative chemotherapy and surgery and surgery with alone in resectable stage IIIa non-small cell lung cancer. Lung Cancer 21, 1-6 (1998).
57. Rosell R, Gomez-Codina J, Camps C et al. Preresectional chemotherapy in stage IIIa non-small cell lung cancer: A 7-year assessment of a randomised controlled trial. Lung Cancer 47, 7-14 (1999).
58. Preoperative chemotherapy in resectable NSCLC. The LU22 protocol. MRC Clinical Trials Unit, 222 Euston Road, London NW1 2DA, UK (2002).
59. Ware JE, Shebourne CD. The MOS 36-item short-form health survey (SF-36). Medical Care 30, 473-483 (1992).
60. De Haes JCJM, van Knippenberg FCE, Neijt JP. Measuring psychological and physical distress in cancer patients: Structure and application of the Rotterdam Symptom Checklist. Br. J. Cancer 62, 1034-1038 (1990).
61. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta. Psychiatr. Scand. 67, 361-370 (1983).
62. Bailey AJ, Parmar MK, Stephens RJ on behalf of the CHART Steering Committee. Patient-reported short-term and long-term physical and psychologic symptoms: Results of the continuous hyperfractionated accellerated radiotherapy (CHART) randomised trial in non-small cell lung cancer. J. Clin. Oncol. 16, 3082-3093 (1998).
63. Bergman B, Aaronson NK, Ahmedzai S, Kaasa S, Sullivan M. The EORTC QLQ-LC13: A modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials. Eur. J. Cancer 30, 635-642 (1994).
64. Furuse K, Fukoka M, Kawahara M et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine and cisplatin in unresectable stage III non-small cell lung cancer. J. Clin. Oncol. 17, 2692-2699 (1999).
65. Zatloukal PV, Petruzelka L, Zemanova M et al. Concurrent versus sequential radiochemotherapy with vinorelbine plus cisplatin (V-P) in locally advanced non-small cell lung cancer. A randomised Phase III study. Proceed. Am. Soc. Clin. Oncol. 21, 290a, abs 1159 (2002).
66. Mornex F, Robinet G, Thomas P et al. Sequential versus concurrent chemoradiation (RT-CT) in locally advanced non-small cell lung cancer (NSCLC): A French randomised Phase III trial of GLOT-GFPC (NPC 95-01 study). Eur. J. Cancer 37(Suppl. 6), S28, abs 93 (2001).
67. Choy H, Curran WJ, Scott CB et al. Preliminary report of locAlly advanced multimodality protocol (LAMP): ACR 427: a randomised Phase II study of three chemo-radiation regimens with paclitaxel, carboplatin and thoracic radiation (TRT) for patients with locally advanced non-small cell lung cancer (LA-NSCLC). Proceed. Am. Soc. Clin. Oncol. 21, 291a, abs 1160 (2002).
68. Curran WJ, Scott CB, Langer CJ et al. Long-term benefit is observed in a Phase III comparison of sequential versus concurrent chemo-radiation for patients with unresected stage III NSCLC: RTOG 9410. Proceed. Am. Soc. Clin. Oncol. 22, 621, abs 2499 (2003).
69. Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality of life instrument for use in international clinical trials in oncology. J. Natl Cancer Inst. 85, 365-376 (1993).
70. Hopwood P, Stephens RJ. Symptoms at presentation for treatment in patients with lung cancer: Implications for the evaluation of palliative treatment. Br. J. Cancer 71, 633-636 (1995).
71. Hopwood P, Stephens RJ. Depression in patients with lung cancer: Prevalence and risk factors derived from quality of life data. J. Clin. Oncol. 18, 893-903 (2000).
72. Moinpour CM, Lyons B, Grevstad PK et al. Quality of life in advanced non-small cell lung cancer: Results of a Southwest Oncology Group randomized trial. Qual. Life Res. 11, 115-126 (2002).
73. Hollen PJ, Gralla RJ, Kris MG et al. Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the Lung Cancer Symptom Scale. Cancer 73, 2087-2098 (1994).
74. Dancey J, Shepherd FA, Gralla RJ, Kim YS. Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy: Results of a prospective, randomized Phase III trial. Lung Cancer 43, 183-194 (2004).
75. Fayers P. MRC quality of life studies using a daily diary card - practical lessons learned from cancer trials. Qual. Life Res. 4, 343-352 (1995).
76. Stephens RJ, Hopwood P, Girling DJ. Defining and analysing symptom palliation in cancer clinical trials: A deceptively difficult exercise. Br. J. Cancer 79, 538-544 (1999).
77. Langendijk JA, ten Velde GPM, Aaronson NK, de Jong JMA, Muller MJ, Wouters EFM. Quality of life after palliative radiotherapy in non-small cell lung cancer: A prospective study. Int. J. Rad. Oncol. Biol. Phys. 47, 149-155 (2000).
78. Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality of life scores. J. Clin. Oncol. 16, 139-44 (1998).
79. King MT. The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Qual. Life Res. 5, 555-567 (1996).
80. Groenvold M, Fayers PM. Testing for differences in multiple quality of life dimensions: Generating hypotheses from the experiences of hospital staff. Qual. Life Res. 7, 479-486 (1998).
81. Cella DF, Bonomi AE, Lloyd SR, Tulsky DS, Kaplan E, Bonomi P. Reliability and validity of the Functional Assessment of Cancer Therapy - Lung (FACT-L) quality of life instrument. Lung Cancer 12, 199-220 (1995).
82. Bergner M, Bobbit RA, Carter WB, Gilson BS. The Sickness Impact Profile: Development and final revision of a health status measure. Med. Care 19, 787-805 (1981).
83. Morrow GR, Lindke J, Black P. Measurement of quality of life in patients: Psychometric analyses of the Functional Living Index - Cancer (FLIC). Qual. Life Res. 1, 287-296 (1992)
84. Fayers P. Quality of life assessment in small cell lung cancer. PharmacoEconomics 2, 181-188 (1992).
85. Sadura A, Pater J, Osoba D, Levine M, Palmer M, Bennett K. Quality of life assessment: Patient compliance with questionnaire completion. J. Natl. Cancer Inst. 84, 1023-1026 (1992).
86. De Haes JCJM, Olschewski M, Fayers P et al. Measuring the Quality of Life of cancer patients with the Rotterdam Symptom Checklist (RSCL). A manual. Northern Centre for Healthcare Research, University of Groningen, The Netherlands (1996).
87. Curran D, Aaronson N, Standaert B et al. Summary measures and statistics in the analysis of quality of life data: An example from an EORTC-NCIC-SAKK locally advanced breast cancer study. Eur. J. Cancer 36, 834-843 (2000).
88. Qian W, Parmar MKB, Sambrook RJ, Fayers PM, Girling DJ, Stephens RJ. Analysis of messy longitudinal data from a randomised clinical trial. Statist. Med 19, 2657-2674 (2000).
89. Brundage MD, Mackillop WJ. Locally advanced non-small cell lung cancer: Do we know the questions? A survey of randomized trials from 1966 to 1993. J. Clin. Epidemiol. 49, 183-192 (1996).